Anti-Human CD28 Reference Antibody (Theralizumab, RUO) (HY422026)

Name: Anti-Human CD28 Reference Antibody (Theralizumab, RUO)
Brand: abinScience
SKU: HY422026
Price: 320 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY422026
Descripción	Theralizumab (HY422026) is a research-grade recombinant antibody targeting CD28. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4
Sistema de expresión	Mammalian cells
Objetivo	CD28, TP44, T-cell-specific surface glycoprotein CD28
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P10747
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	TGN1412, TAB08, TAB-08, CD28-SuperMAB, 906068-56-2
Fondo	T-cell-specific surface glycoprotein CD28 is a ~25 kDa protein. Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis. Functions not only as an amplifier of TCR signals but delivers unique signals that control intracellular biochemical events that alter the gene expression program of T-cells. Stimulation upon engagement of its cognate ligands CD80 or CD86 increases proliferation and expression of various cytokines in particular IL2 production in both CD4(+) and CD8(+) T-cell subsets. Mechanistically, ligation induces recruitment of protein kinase C-theta/PRKCQ and GRB2 leading to NF-kappa-B activation via both PI3K/Akt-dependent and -independent pathways. In conjunction with TCR/CD3 ligation and CD40L costimulation, enhances the production of IL4 and IL10 in T-cells. 1. Gimmi, CD. et al. (1991) Proceedings of the National Academy of Sciences of the United States of America 88, 6575-9. PMID: 1650475 2. Raab, M. et al. (1995) Proceedings of the National Academy of Sciences of the United States of America 92, 8891-5. PMID: 7568038 3. Skånland, SS. et al. (2014) The Biochemical journal 460, 399-410. PMID: 24665965 4. Collins, AV. et al. (2002) Immunity 17, 201-10. PMID: 12196291 5. Wu, H. et al. (2022) Structure (London, England : 1993) 30, 803-812.e5. PMID: 35397202 6. Kong, KF. et al. (2011) Nature immunology 12, 1105-12. PMID: 21964608 7. Blotta, MH. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 156, 3133-40. PMID: 8617933
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)